Two Sigma Investments LP Has $2.03 Million Stake in C4 Therapeutics, Inc. (NASDAQ:CCCC)

Two Sigma Investments LP trimmed its holdings in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 31.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 563,837 shares of the company's stock after selling 264,653 shares during the period. Two Sigma Investments LP owned 0.80% of C4 Therapeutics worth $2,030,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of CCCC. Sei Investments Co. acquired a new position in shares of C4 Therapeutics in the 4th quarter valued at $45,000. Kazazian Asset Management LLC bought a new position in C4 Therapeutics during the fourth quarter worth about $51,000. China Universal Asset Management Co. Ltd. bought a new position in C4 Therapeutics during the fourth quarter worth about $54,000. ProShare Advisors LLC lifted its holdings in C4 Therapeutics by 83.1% during the fourth quarter. ProShare Advisors LLC now owns 20,283 shares of the company's stock worth $73,000 after acquiring an additional 9,204 shares in the last quarter. Finally, Lazard Asset Management LLC bought a new position in C4 Therapeutics during the fourth quarter worth about $81,000. Institutional investors own 78.81% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, UBS Group upgraded C4 Therapeutics to a "hold" rating in a report on Friday, February 14th.

C4 Therapeutics Price Performance

Shares of C4 Therapeutics stock traded down $0.07 on Thursday, hitting $1.47. The company had a trading volume of 767,957 shares, compared to its average volume of 1,378,712. The firm has a market capitalization of $104.38 million, a P/E ratio of -0.86 and a beta of 2.93. C4 Therapeutics, Inc. has a twelve month low of $1.09 and a twelve month high of $7.66. The stock has a 50-day moving average of $1.41 and a 200-day moving average of $2.70.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.11. The company had revenue of $7.20 million during the quarter, compared to analysts' expectations of $3.54 million. C4 Therapeutics had a negative net margin of 313.35% and a negative return on equity of 42.45%. Equities analysts predict that C4 Therapeutics, Inc. will post -1.52 EPS for the current year.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.